Serum Talin-1 and Cripto-1 in Colorectal Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Serum level of Human Talin-1, Serum level of Human Cripto-1.
- Who it may be relevant to
- Registry conditions: Colo-rectal Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluating Serum Talin-1 and Cripto-1 as Diagnostic Biomarkers in Colorectal Cancer
Overview
The goals of this study are * To evaluate the clinical utility of Talin-1 and Cripto-1 measurement in colorectal cancer patients in comparison with healthy controls. * To Compare the diagnostic significance of serum Talin-1 and Cripto-1 with traditional serum biomarker CEA
Detailed description
Colorectal cancer (CRC) is a major global health concern, ranking as the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths. CRC is a malignancy predominantly affecting older adults, posing significant threats to their health and creating formidable challenges for healthcare systems.
Compared to younger patients, elderly CRC often presents with atypical symptoms. In some cases, the initial manifestations are not hematochezia or abdominal pain but anaemia and weight loss, leading to frequent late-stage (Stage IV) diagnoses, which complicates treatment.
Talin-1 serves as a crucial element within the multiprotein adhesion complexes that facilitate processes such as cell migration, adhesion, and integrin signalling. It has been demonstrated that the level of Talin-1 in the serum of colon cancer patients was significantly higher than that of healthy controls. Talin-1 may be a valuable biomarker for colon cancer, which may be essential for the early detection, especially in combination with other markers in population screenings that are currently used to detect the colon cancer.
Human Cripto-1 (CR-1) is an embryonic gene, belonging to the EGF-CFC gene family, which is necessary for promoting early stages of embryonic development. CR-1 is a good example of a multifaceted embryonic protein that is re-expressed in most human tumors, particularly colorectal tumor, but not detected in normal adult human tissues. García-Sanmartín et al. showed that Cripto-1 expression was significantly correlated with worse prognosis in CRC, and was an independent prognostic factor.
Interventions
- Diagnostic test Serum level of Human Talin-1
To evaluate the clinical utility of Talin-1 measurement in colorectal cancer patients in comparison with healthy controls. - Diagnostic test Serum level of Human Cripto-1
To evaluate the clinical utility of Cripto-1 measurement in colorectal cancer patients in comparison with healthy controls.
Primary outcome measures
- Serum Talin-1 measurement in colorectal cancer patients [Time frame: From enrollment up to one week]
Secondary outcome measures (1)
- Serum Cripto-1 measurement in colorectal cancer patients [Time frame: From enrollment up to one week]
Eligibility criteria
Inclusion criteria
- Age >18 years Old.
- Patients of both sexes who met the clinical diagnostic criteria of colorectal cancer (change in bowel habit, absolute or recurrent constipation, rectal bleeding, significant weight loss or intestinal obstruction)
- Patients diagnosed with colorectal cancer by imaging and histopathology
Exclusion criteria
- Age <18 years old.
- Patients with past history of chemotherapy or surgical excision of tumor
- Patients with familial adenomatous polyposis
- Patients with hereditary non-polyposis colorectal cancer
- Patients with inflammatory bowel disease
- patients with other types of tumors
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
Egypt · 1 center
- Assuit University Hospital — Asyut
Identifiers
NCT: NCT07414082 · SHROOK